In a major step towards preventive and tech-enabled healthcare, Vidal Health, India’s second-largest TPA service provider, has announced a strategic partnership with the Serum Institute of India (SII), the world’s largest vaccine manufacturer and part of the Cyrus Poonawalla Group, to support the national effort in cervical cancer prevention. Starting October 1, 2025, Vidal Health will launch a first-of-its-kind digital platform offering a seamless, cashless HPV vaccination program. The service will enable users to schedule doctor appointments, give digital consent, receive vaccination certificates, and track the full vaccination cycle — all without paperwork.
The initiative also includes automated reminders, dosage tracking, and a managed network of clinics and health professionals to ensure consistent care delivery and adherence. Vidal Health, a wholly owned subsidiary of Bajaj Finserv Health, plays a key role in integrating preventive and outpatient healthcare across digital channels. Bajaj Finserv Health offers a wide range of solutions including diagnostics, OPD care, telemedicine, wellness plans, and healthcare financing.
Sanjiv Bajaj, Chairman & Managing Director, Bajaj Finserv, said “The future of healthcare in India lies in shifting from reactive care to preventive action. This partnership with Serum Institute is a step in that direction—helping individuals and employers take charge of health while reducing long-term costs. We’re proud to build digital infrastructure that empowers this shift.”
Adar Poonawalla, CEO, Serum Institute of India, added “Access and awareness are vital to increasing HPV vaccine coverage. By collaborating with Vidal Health, we’re using technology to streamline vaccine delivery at scale, making cervical cancer prevention more accessible and impactful.”
Neetha Uthaiah, Whole-Time Director, Vidal Healthcare Services Ltd, said “This collaboration enhances our goal of making preventive healthcare more inclusive. By combining our claims processing capabilities and wellness programs with SII’s vaccine expertise, we can help lower medical expenses and reduce hospitalisations.”
The HPV vaccination initiative brings together healthcare providers, vaccine manufacturers, and national digital platforms such as Aarogya Setu, creating a stronger, connected healthcare ecosystem. It also expands Vidal Health’s portfolio in preventive care. The program ensures direct access to WHO-approved HPV vaccines via Vidal’s digital platform, eliminating intermediaries and delays. Corporate employees will have the option to get vaccinated at partner clinics or on company premises, depending on convenience.
Bajaj Finserv Health is a leading health-tech company focused on preventive, personalized, and partner-led care. Its services span across consultations, diagnostics, health financing, and wellness programs. Vidal Health, a 100% subsidiary, offers TPA services and a digital-first approach to healthcare access and administration, serving both individuals and corporate clients.
Founded in 1966, Serum Institute of India Pvt Ltd is the world’s largest vaccine manufacturer by volume. Part of the Cyrus Poonawalla Group, SII has distributed vaccines to over 170 countries, including the US, UK, and European Union. It has played a pivotal role in reducing the cost of essential vaccines globally and saving millions of lives.
